BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Jung YS, Han M, Park S, Cheon JH. Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease. Gut Liver 2021;15:92-9. [PMID: 32839359 DOI: 10.5009/gnl19377] [Reference Citation Analysis]
2 Sun Z, Li J, Dai Y, Wang W, Shi R, Wang Z, Ding P, Lu Q, Jiang H, Pei W, Zhao X, Guo Y, Liu J, Tan X, Mao T. Indigo Naturalis Alleviates Dextran Sulfate Sodium-Induced Colitis in Rats via Altering Gut Microbiota. Front Microbiol 2020;11:731. [PMID: 32425906 DOI: 10.3389/fmicb.2020.00731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jung YS, Han M, Park S, Cheon JH. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Dig Dis Sci 2020;65:1436-44. [PMID: 31677070 DOI: 10.1007/s10620-019-05867-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Jeon SR, Kim JO, Byeon JS, Yang DH, Ko BM, Goong HJ, Jang HJ, Park SJ, Kim ER, Hong SN, Im JP, Kim SE, Koo JS, Eun CS, Chang DK; Korean Association for the Study of Intestinal Diseases (KASID). Enteroscopy in Crohn's Disease: Are There Any Changes in Role or Outcomes Over Time? A KASID Multicenter Study. Gut Liver 2021;15:375-82. [PMID: 32616680 DOI: 10.5009/gnl20023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Yoon JY, Cha JM, Lee CK, Park YS, Huh KC, Shin JE, Kim YS, Eun CS, Yoon SM, Cheon JH, Park YS, Ye BD, Lee Y, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for the Study of Intestinal Diseases (KASID). Early course of newly diagnosed moderate-to-severe ulcerative colitis in Korea: Results from a hospital-based inception cohort study (MOSAIK). J Gastroenterol Hepatol 2021;36:2149-56. [PMID: 33555067 DOI: 10.1111/jgh.15435] [Reference Citation Analysis]
7 Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1089-100. [PMID: 33181088 DOI: 10.1016/S2468-1253(20)30298-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Park SH, Park SH. Personalized medicine in inflammatory bowel disease: Perspectives on Asia. J Gastroenterol Hepatol 2022. [PMID: 35726657 DOI: 10.1111/jgh.15919] [Reference Citation Analysis]
9 Park SK, Kim S, Lee GY, Kim SY, Kim W, Lee CW, Park JL, Choi CH, Kang SB, Kim TO, Bang KB, Chun J, Cha JM, Im JP, Ahn KS, Kim SY, Park DI. Development of a Machine Learning Model to Distinguish between Ulcerative Colitis and Crohn's Disease Using RNA Sequencing Data. Diagnostics (Basel) 2021;11:2365. [PMID: 34943601 DOI: 10.3390/diagnostics11122365] [Reference Citation Analysis]
10 Park MY, Yoon YS, Lee JL, Park SH, Ye BD, Yang SK, Yu CS. Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn's disease: a retrospective observational study. Stem Cell Res Ther 2021;12:401. [PMID: 34256838 DOI: 10.1186/s13287-021-02484-6] [Reference Citation Analysis]
11 Yasuda T, Takagi T, Asai J, Katoh N, Kuroda J, Kuwahara Y, Morinaga Y, Konishi E, Uchiyama K, Naito Y, Itoh Y. Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy. Clin J Gastroenterol 2021;14:170-5. [PMID: 33219936 DOI: 10.1007/s12328-020-01277-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Lee SH, Walshe M, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Greener T, Weizman AV, Silverberg MS, Ye BD. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. Inflamm Bowel Dis. 2020;. [PMID: 33269403 DOI: 10.1093/ibd/izaa309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Banerjee R, Pal P, Mak JWY, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1076-88. [PMID: 33181087 DOI: 10.1016/S2468-1253(20)30299-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
14 Hong HS, Kim K, Oh K, Lee JY, Hong SW, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn's disease: a retrospective study. Therap Adv Gastroenterol 2021;14:17562848211043017. [PMID: 34539814 DOI: 10.1177/17562848211043017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ansari MN, Rehman NU, Karim A, Soliman GA, Ganaie MA, Raish M, Hamad AM. Role of Oxidative Stress and Inflammatory Cytokines (TNF-α and IL-6) in Acetic Acid-Induced Ulcerative Colitis in Rats: Ameliorated by Otostegia fruticosa. Life (Basel) 2021;11:195. [PMID: 33802553 DOI: 10.3390/life11030195] [Reference Citation Analysis]
16 Lee SY. Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine. Ann Lab Med 2020;40:95-6. [PMID: 31650723 DOI: 10.3343/alm.2020.40.2.95] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, Kim ES, Jung Y, Eun CS, Kim TO, Kang SB, Kim YS, Seo GS, Lee CK, Im JP, Park SJ, Park DI, Ye BD. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Inflamm Bowel Dis 2021:izaa361. [PMID: 33501935 DOI: 10.1093/ibd/izaa361] [Reference Citation Analysis]
18 Jung YS, Han M, Park S, Cheon JH. Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study. Korean J Intern Med 2020;35:1104-13. [PMID: 32306709 DOI: 10.3904/kjim.2020.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Yen H, Hsu Y, Kuo C, Hsu T, Chen Y. Real‐world experience of adalimumab therapy for patients with ulcerative colitis: A single tertiary medical center experience in Central Taiwan. Adv in Digestive Medicine. [DOI: 10.1002/aid2.13300] [Reference Citation Analysis]
20 Cha JM, Park SH, Rhee KH, Hong SN, Kim YH, Seo SI, Kim KH, Jeong SK, Lee JH, Park SY, Park H, Kim JS, Im JP, Yoon H, Kim SH, Jang J, Kim JH, Suh SO, Kim YK, Ye BD, Yang SK. Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut 2020;69:1432-40. [PMID: 31822581 DOI: 10.1136/gutjnl-2019-319699] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
21 Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory Bowel Disease - Non-biological treatment. Pharmacol Res 2020;160:105075. [PMID: 32653651 DOI: 10.1016/j.phrs.2020.105075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
22 Lee JW, Song EM, Jung SA, Jung SH, Kim KW, Koh SJ, Lee HJ, Hong SW, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study. J Korean Med Sci 2021;36:e336. [PMID: 34904410 DOI: 10.3346/jkms.2021.36.e336] [Reference Citation Analysis]
23 Jeon SR. Use of small bowel capsule endoscopy in clinical practice: how has it performed? Korean J Intern Med 2020;35:854-6. [PMID: 32668517 DOI: 10.3904/kjim.2020.291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Yen HH, Hsu TC, Chen MW, Su PY, Chen YY. Clinical features and treatment of inflammatory bowel disease in a low-incidence area: A hospital-based retrospective cohort study in Taiwan. Medicine (Baltimore) 2021;100:e25090. [PMID: 33725901 DOI: 10.1097/MD.0000000000025090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kim JM, Kim DH, Park HJ, Ma HW, Park IS, Son M, Ro SY, Hong S, Han HK, Lim SJ, Kim SW, Cheon JH. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. J Nanobiotechnology 2020;18:133. [PMID: 32933548 DOI: 10.1186/s12951-020-00693-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
26 Lee SH, Chang K, Seo KS, Cho YK, Song EM, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey. Intest Res 2020;18:192-9. [PMID: 32238788 DOI: 10.5217/ir.2019.00115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Han M, Jung YS, Cheon JH, Park S. Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study. Yonsei Med J 2020;61:382-90. [PMID: 32390361 DOI: 10.3349/ymj.2020.61.5.382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Jo HG, Seo GS. [Efficacy and Safety of Fecal Microbiota Transplantation and Prospect of Microbe-based Therapies for Inflammatory Bowel Disease]. Korean J Gastroenterol 2021;78:31-6. [PMID: 34312355 DOI: 10.4166/kjg.2021.089] [Reference Citation Analysis]
29 Yang S. Current status of inflammatory bowel diseases in Korea. J Korean Med Assoc 2021;64:572-7. [DOI: 10.5124/jkma.2021.64.9.572] [Reference Citation Analysis]
30 Noh SM, Oh EH, Park SH, Lee JB, Kim JY, Park JC, Kim J, Ham NS, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy. J Crohns Colitis 2020;14:1231-40. [PMID: 32157278 DOI: 10.1093/ecco-jcc/jjaa042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]
33 Kim YS. Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis? Intest Res 2021;19:357-9. [PMID: 34731562 DOI: 10.5217/ir.2021.00120] [Reference Citation Analysis]
34 Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Wei S, Sollano J, Hui YT, Yu W, Santos Estrella PV, Llamado LJQ, Koram N. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Review of Gastroenterology & Hepatology 2021;15:275-89. [DOI: 10.1080/17474124.2021.1840976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Jung YS. Trends in Healthcare Costs for Inflammatory Bowel Disease in South Korea. Gut Liver 2020;14:3-4. [PMID: 31945814 DOI: 10.5009/gnl19374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Yoon H. Another Piece of Evidence for Early Administration of Biologics in Children with Crohn's Disease Who Start as an Inflammatory Phenotype. Gut Liver 2021;15:791-2. [PMID: 34782486 DOI: 10.5009/gnl210508] [Reference Citation Analysis]